Aviso Financial Inc. Boosts Position in Medtronic PLC $MDT

Aviso Financial Inc. raised its holdings in shares of Medtronic PLC (NYSE:MDT) by 3.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,551 shares of the medical technology company’s stock after acquiring an additional 966 shares during the period. Aviso Financial Inc.’s holdings in Medtronic were worth $2,402,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in MDT. 1248 Management LLC purchased a new stake in Medtronic in the first quarter valued at $26,000. Twin Tree Management LP purchased a new position in shares of Medtronic during the 1st quarter valued at about $29,000. Activest Wealth Management raised its stake in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after buying an additional 322 shares during the last quarter. GFG Capital LLC acquired a new position in shares of Medtronic in the 2nd quarter valued at about $36,000. Finally, True Wealth Design LLC boosted its stake in shares of Medtronic by 49.8% in the second quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock worth $37,000 after buying an additional 140 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.26% of the stock is currently owned by company insiders.

Medtronic Stock Up 2.1%

MDT stock opened at $103.36 on Tuesday. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $103.70. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The firm has a 50-day simple moving average of $95.24 and a 200-day simple moving average of $91.14. The stock has a market capitalization of $132.58 billion, a P/E ratio of 28.47, a P/E/G ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the company posted $1.26 EPS. Medtronic’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MDT. Daiwa Capital Markets lifted their price target on Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Truist Financial raised their price objective on shares of Medtronic from $103.00 to $110.00 and gave the stock a “hold” rating in a research note on Thursday, November 20th. Wells Fargo & Company lifted their target price on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Cowen reissued a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Finally, Royal Bank Of Canada raised their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and an average price target of $109.72.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.